PGD is a method of detecting chromosomal and genetic abnormalities in embryos before they are implanted into the uterus, conducted at the end of an IVF cycle. It is used for patients at risk of transmitting specific chromosomal and genetic abnormalities to their children. Since 1996, experts at the Centre for Reproductive and Genetic Health have been working with University College London Centre for PGD to offer our patients the full range of highly specialist PGD services from one of the world's leading centres of excellence.
The PGD team at University College London is headed by Professor Joy Delhanty and Dr Joyce Harper, both pioneers in the field. The world-renowned partnership between our two organisations has led the UK's development of PGD, and set many national firsts. These include the first baby conceived free of the breast cancer gene, the first baby born free of retinoblastoma (a form of eye cancer) and the first centre to test for Familial Adenomatous Polyposis (FAP) which can lead to early onset colon cancer.
In addition, we are one of the few clinics to have a clinical nurse specialist in genetics who is an expert on PGD leading our services. If PGD is right for you then Karen will personally look after you throughout your whole journey with us, overseeing all your appointments and tests and answering your queries along the way.
Aneuploidy screening (PGS)
At the Centre for Reproductive and Genetic Health, we are able to scan embryos to pick those most likely to result in a healthy, successful pregnancy, before implanting them into the womb. This is done through a microscopic examination of the chromosomes within the embryos; a procedure known as PGS (preimplantation genetic screening).
Your consultant will be able to advise you on the most appropriate course of action for you and answer your questions.